{"id":958135,"date":"2026-05-05T08:50:45","date_gmt":"2026-05-05T12:50:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/"},"modified":"2026-05-05T08:50:45","modified_gmt":"2026-05-05T12:50:45","slug":"lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/","title":{"rendered":"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026<\/b><\/p>\n<p>CARLSBAD, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54523807&amp;newsitemid=20260505977292&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=bf69e7e5deb4cf02bb0fb95cb3256905\">Lineage Cell Therapeutics, Inc.<\/a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing \u201coff the shelf\u201d allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update.<\/p>\n<p><b>Conference Call and Webcast<\/b><\/p>\n<p>\nInterested parties may access the conference call on May 12, 2026, by dialing (800) 715-9871 from the U.S. and Canada and should request the \u201cLineage Cell Therapeutics Call\u201d (Conference ID: 9229676). A live webcast of the conference call will be available online in the Investors section of Lineage\u2019s website. A replay of the webcast will be available on Lineage\u2019s website for 30 days and a telephone replay will be available through May 19, 2026, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 9229676.<\/p>\n<p><b>About Lineage Cell Therapeutics, Inc.<\/b><\/p>\n<p>\nLineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or \u201coff the shelf\u201d, cell therapies for serious medical conditions. Lineage\u2019s programs are based on its proprietary cell-based technology platform, AlloSCOPE\u2122 (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and associated development and manufacturing capabilities. From this proprietary AlloSCOPE platform, Lineage develops, manufactures, and tests specialized human cells with anatomical and physiological functions similar or substantially identical to cells found naturally in the human body. These cells are created by applying directed differentiation protocols to established, well-characterized, and self-renewing pluripotent cell lines. These protocols generate cells with characteristics associated with specific and desired developmental lineages, and in some instances may be designed to have additional beneficial properties. Cells derived from such lineages are transplanted into patients in an effort to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, and to restore or augment the patient\u2019s functional activity. Lineage\u2019s pipeline currently includes: (i) OpRegen<sup>\u00ae<\/sup> cell therapy, a retinal pigment epithelial cell therapy in Phase 2a development under a worldwide collaboration with Roche and Genentech, a member of the Roche Group, for the treatment of geographic atrophy secondary to age-related macular degeneration; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1\/2a development for the treatment of spinal cord injuries; (iii) ReSonance<sup>TM<\/sup> (ANP1), an auditory neuronal progenitor cell therapy in preclinical development under a collaboration with William Demant Invest A\/S for the potential treatment of auditory neuropathy; (iv) PNC1, a photoreceptor neural cell therapy research initiative being evaluated for development for the potential treatment of vision loss due to photoreceptor dysfunction or damage; (v) RND1, a novel hypoimmune induced pluripotent stem cell line being evaluated for development under a gene editing partnership; (vi) ILT1, a cell therapy research initiative focused on the issue of large-scale production of undifferentiated pluripotent cells, which if successful could be evaluated for the production of islet cells to support a potential treatment of Type 1 Diabetes; and (vii) COR1, a corneal endothelial disease cell therapy in preclinical development for the potential treatment of corneal endothelial disease. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54523807&amp;newsitemid=20260505977292&amp;lan=en-US&amp;anchor=www.lineagecell.com&amp;index=2&amp;md5=276e8eef2bc10b08b49f63399b8260ad\">www.lineagecell.com<\/a> or follow the company on X\/Twitter <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FLineageCell&amp;esheet=54523807&amp;newsitemid=20260505977292&amp;lan=en-US&amp;anchor=%40LineageCell&amp;index=3&amp;md5=6dec0e33c6713ca1223af5279b81007f\">@LineageCell<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nLineage cautions you that all statements, other than statements of historical fact, contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terms such as \u201cbelieve,\u201d \u201caim,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201ccould,\u201d \u201ccan,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cseek,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccontemplate,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201cgoal,\u201d \u201csuggest,\u201d or the negative version of these words and similar expressions. Such forward-looking statements include, but are not limited to, statements relating to our ability to develop new cell lines into potential differentiated cell transplant product candidates and the potential indications thereof. Forward-looking statements are based upon our current expectations, involve assumptions that may never materialize or may prove to be incorrect, and involve known and unknown risks, uncertainties and other factors that may cause Lineage\u2019s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by forward-looking statements, including, but not limited to, the risks that: investigational allogeneic cell therapies represent a novel approach to the treatment of serious medical conditions, which gives rise to significant challenges; clinical development of product candidates is a lengthy and expensive process with a high level of uncertainty as to timing and ultimate outcome; we may not be successful in developing new product candidates and neither we nor our collaborators may be successful in obtaining regulatory approval to market and sell any product candidates; that the ongoing Israeli regional conflict may materially and adversely impact our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, all of which are conducted by our subsidiary in Jerusalem, Israel; that Lineage may not be able to manufacture sufficient clinical quantities of its product candidates in accordance with current good manufacturing practice; and those risks and uncertainties inherent in Lineage\u2019s business and other risks discussed in Lineage\u2019s filings with the Securities and Exchange Commission (SEC). Further information regarding these and other risks is included under the heading \u201cRisk Factors\u201d in Lineage\u2019s periodic reports with the SEC, including Lineage\u2019s most recent Annual Report on Form 10-K filed with the SEC and its other subsequent reports, which are available on the SEC\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54523807&amp;newsitemid=20260505977292&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=4&amp;md5=b74f7d6a65c0159374915e5c2157f123\">www.sec.gov<\/a>. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Lineage undertakes no obligation to update any forward-looking statement to reflect events that occur or circumstances that exist after the date on which they were made except as required by law.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260505977292\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260505977292\/en\/<\/a><\/span><\/p>\n<p><b>Lineage Cell Therapeutics, Inc. IR<br \/>\n<\/b><br \/>Ioana C. Hone<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:ir@lineagecell.com\">ir@lineagecell.com<\/a>)<br \/>\n<br \/>(442) 287-8963<\/p>\n<p><b>Russo Partners \u2013 Media Relations<br \/>\n<\/b><br \/>Nic Johnson or David Schull<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:Nic.johnson@russopartnersllc.com\">Nic.johnson@russopartnersllc.com<\/a>)<br \/>\n<br \/>(<a rel=\"nofollow\" href=\"mailto:David.schull@russopartnersllc.com\">David.schull@russopartnersllc.com<\/a>)<br \/>\n<br \/>(212) 845-4242<\/p>\n<p><b>KEYWORDS:<\/b> California United States North America Israel Middle East<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Health Technology Pharmaceutical Health<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260505977292\/en\/1765407\/3\/LINEAGE_2023_RGB_JPG_1740x360.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing \u201coff the shelf\u201d allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-958135","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing \u201coff the shelf\u201d allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference &hellip; Continue reading &quot;Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-05T12:50:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026\",\"datePublished\":\"2026-05-05T12:50:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/\"},\"wordCount\":1082,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/\",\"name\":\"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-05-05T12:50:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/","og_locale":"en_US","og_type":"article","og_title":"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Market Newsdesk","og_description":"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 CARLSBAD, Calif.&#8211;(BUSINESS WIRE)&#8211;Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing \u201coff the shelf\u201d allogeneic cell therapies for serious medical conditions, today announced that it will report its first quarter 2026 financial and operating results on Thursday, May 12, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, May 12, 2026, at 4:30 p.m. Eastern Time\/1:30 p.m. Pacific Time to discuss its first quarter 2026 financial and operating results and to provide a business update. Conference Call and Webcast Interested parties may access the conference &hellip; Continue reading \"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-05T12:50:45+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026","datePublished":"2026-05-05T12:50:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/"},"wordCount":1082,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/","name":"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-05-05T12:50:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260505977292r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=958135"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958135\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=958135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=958135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=958135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}